Protocol of the QUATTRO-II study: A multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a firstline treatment in patients with metastatic colorectal cancer

First-line treatment with FOLFOXIRI plus bevacizumab (BEV) is highly effective and regarded as one of the standards-of-care for patients with metastatic colorectal cancer (mCRC), despite the high incidence of neutropenia and diarrhea as side effects. | Protocol of the QUATTRO-II study A multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a firstline treatment in patients with metastatic colorectal cancer

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN